Clinical Trial

Daratumumab in VHR T-ALL Treated According to the ALL National Treatment Program

Study acronym: DARATALL-VHR
Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The goal of this clinical trial is to test daratumumab in adult very high risk T-lineage lymphoblastic leukemia. The main question it aims to answer is wether the addition of daratumumab daratumumab to the national standard of care is able to increase the rate of MRD-negative patients after induction therapy. Participants will be treated with: • daratumumab in combination with a pediatric-inspired treatment scheme - as in the previous GIMEMA LAL1913 protocol.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2024-02-02; most recent amendment 2026-03-04.
Status change: Recruiting → Active, Not Recruiting 2026-03-04
Status change: Not Yet Recruiting → Recruiting 2024-10-21
Trial Details
NCT Number NCT06253637
Lead Sponsor Gruppo Italiano Malattie EMatologiche dell'Adulto
Conditions T-Lymphocytic Leukemia, Acute
Enrollment 31 participants
Start Date 2024-10-17
Primary Completion 2029-10 (estimated)
Study Completion 2029-10 (estimated)
Updated on ClinicalTrials.gov 2026-03-05